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Objective 
To evaluate the long-term survival outcomes of a large cohort 
of liver transplant recipients and to identify static and chang-
ing factors that influenced these outcomes over time. 
Summary Background Data 
Uver transplantation has been accepted as a therapeutic op-
tion for patients with end-stage liver disease since 1983. with 
continual improvements in patient survival as a result of ad-
vances in immunosuppression and medical management, 
technical achievements, and improvements in procurement 
and preservation. Although many reports. including registry 
data. have delineated short-term factors that influence sur-
vival, few reports have examined factors that affect long-term 
survival after liver transplantation. 
Methods 
Four thousand consecutive patients who underwent liver 
transplantation between February 1981 and April 1998 were 
included in this analysis and were followed up to March 2000. 
The effect of donor and recipient age at the time of trans plan-
Although the technique of liver transplantation was inde-
pendently described in 1960. 1•2 it was not until 1963 that the 
first human liver transplantation was performed at the Uni-
versity of Colorado.3 Between 1963 and 1967. nine such 
attempts were made worldwide. with poor outcomes; the 
first meaningful survival of 400 days was not reported until 
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tation, recipient gender, diagnosis. and year of transplantation 
were compared. Rates of retransplantation. causes of re-
transplantation, and cause of death were also examined. 
Results 
The overall patient survival for the entire cohort was 59%; the 
actuarial 18-year survival was 48%. Patient survival was sig-
nificantly better in children, in female recipients, and in pa-
tients who received transplants after 1990. The rates of re-
transplantation for acute or chronic rejection were significantly 
lower with tacrolimus-based immunosuppression. The risk of 
graft failure and death was relatively stable after the first year, 
with recurrence of disease. malignancies. and age-related 
complications being the major factors for loss. 
Conclusion 
Significantly improved patient and graft survival has been ob-
served over time, and graft loss from acute or chronic rejec-
tion has emerged as a rarity. Age-related and disease-related 
causes of graft loss represent the greatest threat to long-term 
survival. 
1967.4 Under azathioprine. corticosteroid. and antilympho-
cyte globulin therapy between 1967 and 1980, 170 liver 
transplants were performed at the University of Colorado. 
with a I-year survival rate of 30%.4 Between 1968 and 
1983. 138 liver transplants were performed in Cambridge 
(UK). with similarly poor outcomes.s With the clinical 
introduction of cyclosporine.6 and by refining cyclosporine 
use with the addition of corticosteroids,' survival rates after 
liver transplantation more than doubled. 
There have been numerous reports on survival outcomes 
after liver transplantation with short- to medium-term fol-
low-up. However, only a few reports are available of long-
term follow-up. 8 -1\ The United Network of Organ Sharing 
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Table 1. PATIENT DISTRIBUTION BY AGE AND ERA 
Era A (1981-1985) Era B (1986-1990) Era C (1991-1998) 
Group Age (yr) n (%) n = 478 (12%) n = 1382 (34.5%) n = 2140 (53.5%) 
:::::2 285 (7.1) 7% 9% 6% 
II 3-18 523 (13.1) 35% 13% 8% 
III 19-60 2524 (63.1) 56% 68% 64% 
IV >60 668 (16.7) 6% 11% 21% 
Total 4,000 
(UNOS) began collecting outcome data in October 1987,12 
but the interpretation of this data is limited by the hetero-
geneity of program practices (e.g., immunosuppression pro-
tocols), differences in categorizing causes of liver disease, Table 2. INDICATIONS FOR LIVER 
and lack of uniformity in follow-up. The aims of our study TRANSPLANTATION 
are to examine the long-term outcome after liver trans- Indications 
plantation in a large population of patients from a single 
Era A Era B Era C Total (n) % 
center with follow-up of up to 18 years and to compare Adults 
the survival patterns, rate of retransplantation, and causes PNCE 10 168 389 567 17.70 
of death in relation to age, diagnosis, gender, and year of PBC 80 163 166 409 12.81 NANB 65 213 91 369 11.56 transplantation. HCV 0 0 311 311 9.74 
Cryptogenic 6 63 210 279 8.74 
PSC 33 93 127 253 7.93 
METHODS Malignancy 22 95 117 234 7,33 HBV 11 91 115 217 6.80 
AI 2 40 105 147 4.60 
The study subjects were 4,000 consecutive patients who Metabolic 13 35 52 100 3.13 
underwent liver transplantation between February 1981, ALF 3 35 38 76 2.38 
when the program was started at the University of Pitts- Secondary biliary Cirrhosis 10 8 20 38 1.19 Budd-Chiari 5 22 12 39 1.22 burgh, and April 1998. They received 4,947 allografts. The Biliary atresia 0 9 4 13 0.41 
remaining 601 patients in our overall liver transplant expe- Congenital hepatic fibrosis 0 4 3 7 0.22 
rience, who were excluded from analysis, included 192 Neonatal hepatitis 0 1 0 1 0.03 
patients who received transplants at the V A Medical Center, Other 16 49 67 132 4.14 
59 who received combined liver/intestinal allografts, and Total Adults 276 1,089 1,827 3,192 Children 
350 who did not have at least 2 years of follow-up. The Biliary atresia 103 168 145 416 51.49 
mean follow-up was 9.4 ::!::: 3.8 years (median 9.6, range Metabolic 38 31 40 109 13.49 
2-18 years). There were 2,172 (54.3%) male patients and ALF 4 21 23 48 5.94 
1,828 (45.7%) female patients. To analyze the effect of a NANB 15 11 7 33 4.08 HCV 0 0 2 2 0.25 
given parameter on survival, parameters that varied during Cryptogenic 8 7 15 30 3.71 
the course of patient accrual (e.g., UNOS status) were Familial cholestasis 14 3 10 27 3.34 
eliminated from analysis. Malignancy 1 10 12 23 2.85 
The study population was divided into four age groups Neonatal hepatitiS 4 9 6 19 2.35 Secondary biliary cirrhosis 3 8 6 17 2.10 based on the recipient's age at the time of transplant. and Congenital hepatic fibroSIS 2 3 10 15 1.86 
into three eras based on the date of the first transplant AI 0 4 4 8 0.99 
(Table I). The three periods coincided with the clinical PSC 1 3 3 7 0.87 
introduction of cyclosporine (era A), the advent of Or- HCV 0 0 2 2 0.25 Budd-Chiari 0 2 3 5 0.62 thoclone OKT3 (Ortho, Raritan, NJ) and Viaspan (Du- HBV 0 1 1 2 0.25 
pont, Wilmington, DE) (era B). and the clinical introduc- PBC 0 0 0 0 0.00 
tion of tacrolimus (era C). The indications for liver Other 9 12 24 45 5.82 
transplant in adults and children in these three eras are Total Children 202 293 313 808 
shown in Table 2. Total Adults + Children 478 1,382 2,140 4,000 
Kaplan-Meier estimates were used to calculate survival AI, autoimmune hepatitis; ALF, acute liver failure; HBV, hepatitis B virus; HCV. 
curves. Differences in survival curves were compared using hepatitis C virus; NANB. non·A/Non·B; PBC, pnmary biliary cirrtlosis: PNCE. 
log-rank statistics. Differences in proportions were tested ethanOl-inducea post necrotIC Clrrt1osIs; PSC, prim8/Y SCllltOSlng ct1oJangrtiS. 
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Figure 1. Overall patient survival 
with comparison of male and fe-
male survival. 
o 
Log Rank: p = 0.0001 
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Years Post Transplantation 
using the chi-square test (or the Fisher exact test). A P value 
less than 0.05 was considered statistically significant. To 
calculate the relative risk of death. regression analysis was 
used and 95% confidence intervals were detennined. 
RESULTS 
Patient Survival 
The actuarial patient survival rates for the entire popula-
tion at 1. 5.10, 15, and IS years were 79%, 67%, 57%, 50%, 
and 4S%. respectively (Fig. 1). Although there was little 
difference in the survival rate in eras A and B. the survival 
rate in era C was significantly better at 1, 5, and 10 years. 
Survival rates were 71%, 59%, and 52% for era A, 7S%, 
63%, and 53% for era B, and S6%, 72%. and 60% for era C, 
respectively (Fig. 2) (P = .0001). 
Survival rates for infants (age 2 years or younger, group 
I), children (age 3-1S years. group [I), adults (age 19-60 
years, group III), and seniors (age older than 60 years, group 
IV) were significantly different. The 1-, 5-, 10-, 15-, and 
IS-year survival rates were 73%, 6S%, 66%. 64%, and 64% 
for group I, SO%, 76%, 72%, 6S%, and 65% for group II, 
and SO%, 67%, 55%. 47%, and 44% for group m. The rates 
for seniors for 1. 5, and 14 years after the transplant were 
76%, 61%, and 30% (Fig. 3) (P = .0001). 
Survival rates for female patients were significantly better 
than for males. with 1-, 5-, 10-, 15-. and IS-year survival 
rates of 77%. 64%. 53%. 44%, and 44% for male patients 
and SO%. 71%. 62%. 56%, and 55% for females (see Fig. 
I). These trends were present regardless of the era analyzed 
(data not shown). 
Survival by cause of primary disease is shown in Table 3. 
The list of diagnoses was condensed into nine categories: 
alcohol-related liver disease: hepatitis C virus and the older 
non-Alnon-B hepatitis: hepatic malignancies; autoimmune 
liver diseases. including primary biliary cirrhosis. primary 
sclerosing cholangitis. and autoimmune hepatitis; hepatitis 
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Figure 2. Survival according to er. 
of transplantation. 
3. 
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B virus; metabolic liver diseases; biliary atresia; acute liver 
failure; and others. Significant differences in survival were 
noted: patients with biliary atresia. metabolic liver diseases. 
and autoimmune liver diseases had better survival rates than 
other patients. There was a significant difference in the 
survival rate of patients with alcohol-related liver disease in 
the late posttransplant period (>5 years) versus patients 
with autoimmune liver diseases (who are approximately 
age-matched). Similar. although not significant. differences 
were also seen in the hepatitis C/non-A/non-B recipients 
after 5 years. 
Causes of Death 
One thousand six hundred thirty-three patients (40.8%) 
died during the follow-up period. The causes of death at 
various time intervals from transplant are shown in Table 4. 
Infection was the most common cause of death at all time 
points, representing 28.4% of all deaths. This was followed 
by recurrent or de novo cancers ( 11.6%) and cardiovascular-
related (8.3%) and respiratory-related (7.0%) deaths. Half of 
all deaths occurred within the first year after the transplant. 
The death rate after 2 years was 1 % to 4% per year (Fig. 4). 
Death often occurred as a result of age-related complica-
tions in groups III and IV (data not shown). 
Graft Survival 
Patient death and retransplantation were considered as 
graft loss. The overall graft survival rates at I. 5. 10. 15. and 
18 years were 70%, 59%. 49%. 44%. and 41 %. Graft 
survival trends were similar to those for patient survival in 
terms of era of transplant. gender. and age at time of 
transplant (Fig. 5). 
Retransplantation 
During the follow-up period. 774 patients (19.4%) re-
ceived two transplants. 148 (3.7%) received three. 20 
(0.5%) received four. and 5 (0.13%) received more than 
four. The rate of retransplantation and the causes of retrans-
plantation in the various eras are shown in Table 5. Overall. 
the rate of retransplantation declined significantly in each 
subsequent era. from 33.4% in era A to 23.7% in era Band 
13.4% in era C (Fig. 6A) (P = .001). This may in part result 
from the length of follow-up; however. in all eras. an equal 
proportion of first retransplants occurred within 30 days 
after the initial transplant (data not shown). Rejection as a 
reason for retransplant declined significantly during the past 
18 years: 13.2% of patients in era A underwent retransplan-
tation for rejection. and this figure decreased to 4.8% in era 
B and 1% in era C (see Fig. 6B) (P = .00l). The rate of 
hepatic artery thrombosis fell from 8.1 % in era A to 6.7% in 
era Band 3.8% in era C (see Fig. 6C). Although the rate of 
primary nonfunction did not appear to change appreciably 
in eras A. B, and C (see Fig. 6D; this rate was 4.6%. 7.0%. 
and 6.0%, respectively). the use of donors older than 50 
years increased from 1.5% in era A to 3.3% in era Band 
22.5% in era C (see Fig. 6E). 
Primary nonfunction and hepatic artery thrombosis were 
the most common causes of retransplantation in all three 
eras. Patient survival rates after retransplantation remained 
considerably poorer compared with primary transplants. 
Patient survival for those who did not undergo retransplan-
tation was 52% for the first transplant versus 32% for the 
second. 25% for the third. and 13% for the fourth of more 
transplant at 10 years (Fig. 7) (P = .001). 
DISCUSSION 
The present study is the largest series of liver transplant 
patients from a single center with this length of follow-up. 
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Other large series exammmg survival trends have been 
reported from the United States, Great Britain, and Cana-
da.9.11.13-15 This study confirms the results of previous 
studies. which demonstrate an increased incidence of late 
graft loss secondary to recurrent diseases, malignancies, and 
cardiovascular and cerebrovascular accidents, although 
there are concerning trends in diagnosis-specific survival for 
patients with alcohol-related liver disease and those with 
hepatitis C/non-Ainon-B. In addition. this study demon-
strates the marked impact of the changing face of immuno-
suppression, with a significant reduction in acute and 
chronic rejection-associated losses. 
With the success of liver transplantation, more patients 
are being referred for it and more patients older than 60 are 
considered for transplants. This age group of patients made 
up the fastest-growing popUlation of transplant patients at 
our center: the number of patients older than 60 increased 
by I8-fold from era A to era C. Although they are carefully 
medically screened before surgery, their long-term survival 
was significantly less than that of other age groups. After the 
first year, the major cause of death was from age-related 
problems, including cardiovascular, respiratory, cerebrovas-
cular, and de novo cancers. 16- 18 
An increasing demand for liver transplantation has forced 
many centers to consider the use of older donors. Since 
1991, more than 20% of the donors were older than 50 
years, traditionally considered as an "expanded" donor and 
reported to have poorer outcomes. 19.20 This compared with 
only 1.5% older donors before 1985 and 3% between 1981 
and 1990. Despite the use of such donors, the overall 
survival rate improved significantly from era A to era C. 
The reasons for these improvements are multiple and in-
clude improved diagnostic and therapeutic measures for 
infectious complications, improved preservation, and the 
delineation of risk factors that affect outcome.21 .22 How-
ever, most notable are the improvements in the immuno-
suppression regimens. The relatively low number of retrans-
plants or graft failures from acute or chronic rejection may 
in part be attributed to the newer immunosuppressive agent 
tacrolimus. which was used for primary therapy in era C and 
for rescue therapy in era 8.23•24 This finding is compatible 
with the observation that tacrolimus offers more freedom 
from rejection and fewer steroid-resistant rejections; the 
result is that graft loss from rejection has become rare.25- 29 
The indications for transplantation in children have not 
changed appreciably during the past 18 years. However. a 
changing pattern of indications in adults was apparent. 
Alcohol-related liver disease is a growing indication and b 
equaled only by hepatitis C. for which detection becamt: 
clinically available III 1991. The impact of the various 
disease processes on long-term outcome is also apparent. In 
adults. recurrent diseases such as primary hepatic malignan-
cies. steatohepatitis. recurrent alcohol abuse. viral hepatitis. 
Budd-Chiari syndrome. primary biliary cirrhosis. primary 
sclerosing cholangitis. and autoimmune hepatitis have been 
reported and variably affect survival.JO - 33 Recurrent disease 
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Table 4. CAUSES OF DEATH DURING FOLLOW-UP PERIOD 
Years After Transplant 
Total 
1 2 3 4 5 6 7 8 9 10 >10 n (%) 
Patients at risk 4,000 2.940 2,685 2,478 2,261 2,018 1,732 1,511 1,238 958 735 
Causes of death 
Infection (bacterial + 372 38 13 16 4 6 8 3 2 464(28.4) 
viral + fungal) 
Malignancy (recurrent 42 45 28 18 11 19 12 6 3 6 190 (11.6) 
+ de novo) 
Cardiovascular 42 14 6 1 13 17 13 9 6 5 9 135 (8.3) 
Respiratory 37 20 14 7 8 3 3 4 5 4 9 114 (7.0) 
Intraoperative 99 4 1 2 4 2 1 113 (6.9) 
Multiorgan system failure 45 16 9 5 6 9 5 7 3 1 3 109 (6.7) 
Uver failure (recurrent 21 15 15 7 10 6 3 2 1 2 82(5.9) 
disease) 
Gastrointestinal 31 6 2 4 5 1 1 52(3.2) 
Central nervous system 20 2 2 4 1 5 3 4 42(2.6) 
Posttransplant 8 5 6 2 3 1 2 29(1.8) 
Iymphoproliferative 
disorder 
Renal failure 8 5 1 3 18 (1.1) 
Rejection (acute + 4 2 1 1 2 2 4 18 (1.1) 
chronic) 
Primary nonfunction 13 1 14 (1.1) 
Miscellaneous 27 15 7 12 10 12 8 10 7 5 5 118 (6.1) 
Unknown 55 20 18 5 5 7 4 5 4 1 11 135 (8.3) 
Total (%) 816 (20.4) 197 (6.7) 122 (4.5) 96 (3.8) 85 (3.7) 93 (4.6) 62 (3.5) 50 (3.3) 36 (2.9) 19 (1.9) 57 (7.7) 1633 
does not occur to the same extent in children, and this 
partially accounts for the significantly better long-term survival 
rate in this population. Even children with the indication of 
primary hepatic malignancy do better than adults (IO-year 
survival rate of 21 % in adults and 50% in children)?4.3S 
With respect to the specific diagnosis for the transplant, 
there were notable trends in early versus late survival. This 
was apparent in patients transplanted for alcohol-related 
liver disease and hepatitis C/non-Alnon-B indications. With 
alcohol-related liver disease, the overall patient survival rate 
2 .3 ... :; 6 7 8 9 10 II 12 Ll I... 15 16 17 18 
Years Post Transplantation 
Figure 4. Changes In death rates over time. 
was not different from other indications,36 but there was a 
significantly different pattern of early versus late survival. 
The early survival rate (0-5 years after the transplant) was 
better compared with those with other indications, but after 
5 years the survival rate was significantly less for those with 
alcohol-related liver disease. The major cause of patient and 
graft survival appeared to be nonimmunologic; this did not 
appear to be related to recidivism. Most late deaths were 
related to de novo cancer and cardiorespiratory and cere-
brovascular events. The risk of death was 2.3 times higher 
for the alcoholic group of patients beyond 5 years after 
transplantation. 
In patients who underwent transplantation for hepatitis C 
virus (previously non-Alnon-B), the impact of hepatitis C 
after the transplant is not clear. The almost universal rein-
fection rate37 and a high incidence of clinical hepatitis 
suggests that long-term survival is compromised. Hepatitis 
C infection after the transplant did not significantly affect 
the 5-year survival rate in several studies with short follow-
up, but it develops into chronic hepatitis in most patients 
and can develop into cirrhosis in a few patients.38.39 In this 
series, the analysis suggests that long-term survival may be 
reduced by recurrent hepatitis C infection. Although there 
was a steady decrease in patient and graft survival rates 
throughout the entire study period. and patient survival was 
not different up to 5 years, in the period after this there was 
a disproportionate decrease (although not significant) in 
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survival when compared with other nonviral. nonmalignant 
indications. 
Recently, it was suggested that patients should not un-
dergo liver transplantation if they have a 5-year life expect-
ancy of less than 50% (Dr. John Lake. American Society of 
Transplantation. personal discussion). Based on the data 
presented here. patients cannot be excluded based on age. 
sex, or diagnosis (excluding adult malignancy). Even these 
criteria are likely to change. Using a multivariate analytic 
approach. Marsh et al40 demonstrated that patients with 
hepatocellular carcinoma without macrovascular invasion 
and without positive lymph nodes had a more than 50% 
chance of surviving 5 years after liver transplantation. 
Because outcomes after retransplantation do not reach 
this threshold, one might initially suggest that patients 
Table 5. CAUSES OF 
RETRANSPLANTATION BY ERA 
Era A Era B Era C 
Causes n (0/0) n (%) n (0/0) Total 
PNF 22 (4.6) 97 (7.0) 131 (6.0) 250 
Hepatic artery thrombosis 39 (8.1) 93 (6.7) 82 (3.8) 214 
RejectIOn 62 (13.2) 67 (4.8) 21 (1.0) 150 
Recurrent disease 5 (1.0) 12 (0.8) 11 (0.5) 28 
Others 32 (6.6) 59 (4.2) ,,\1 (1.9) 132 
Total retransplants 160 328 286 774 
PNF. pnmary nontunctlon. 
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Figure 5. Graft survival according to (A) era, (8) gender, and (C) age 
distribution. 
should not undergo retransplantation. However. various 
analyses have also identified patients who are at higher risk 
for death after retransplantation,21.22.41 and this may im-
prove outcomes for these patients also. 
CONCLUSIONS 
This study demonstrates that liver transplantation contin-
ues to mature. with advances in many surgical and medical 
aspects leading to improved survival rates. An overall pa-
tient survival rate of 48% at 18 years supports the conclu-
sion of the NIH Consensus Development Conference of 
1983 that liver transplantation is "a therapeutic modality for 
end-stage liver disease that deserves broader application." 
This is particularly true with survival rates in the recent era 
being significantly better than during earlier periods. With a 
diminishing rate of retransplantation and lower rates of graft 
loss from acute or chronic rejection with current immuno-
suppressive medications. the prospects for improving long-
tenn survival are encouraging. However, recurrence of the 
original disease and death from age-related problems in the 
older popUlation will likely limit our ability to achieve 
maximum survival outcomes. 
Acknowledgment 
The authors thank Euwaru Gray lor his help in generating lite tiles from 
the ElectrOnic Dalabase Interface for Transplantation (EDIT) for statistical 
analysIs. 
Vol. 232 • No.4 
Era A EraB 
=igure 7. Patient survival after 
Jne, two. three. and more than 
three transplants at 1. 2, 5, and 10 
years after transplantation. 
Long-Term Survival After Liver Transplantation 497 
Era A EraB EraC 
o ,,-_____________ --, 
Era A EraB EnC 
Figure 6. Changes in retransplantation rates according to (A) era, (8) 
indication for rejection, (C) indication for hepatic artery thrombosis, 
and (0) indication for primary nonfunction. Also shown is the increase 
in the rate of older donor use (E). 
EraC 
lll~----------________________________ _ 
9M~~----------------________________ ___ 
UM+-~~~--------____________________ _ 
TM+-~~------~~~ __________________ ___ 
SM+-~~r-------------~~-------------
RM+---~==~ __ ~----____ ~~===-~ __ ~ 
4M+-----~--~--------~~----------------
30+-____ ~~------==~ ____ ~~==~-----w 
OM+---------~======~ __ -=~~~-----
IO+-----------________ ~~====~ __ __ 
l+-----~----__________ ------------------
o 1 Year 2 Year 5 Year 10 Year 15 Year 18 Year 
Years Post Retransplantation 
--lstLTx 
.o-2ndLTx 
-.-3rdLTx 
-->3rd LTx 
498 Jain and Others 
References 
I. Moore FD. Wheeler HB. Demissianos HV. et a1. Experimental whole 
organ transplantation of the liver and of the spleen. Ann Surg 1960: 
152:374-387. 
2. Starzl TE. Kaupp HA Jr. Brock DR. et al. Reconstructive problems in 
canine liver homotransplantation with special reference to the postop-
erative role of hepatic venous flow. SUfg Gynecol Obstet 1960; Ill: 
733-743. 
3. Starzl TM. Marchioro TL. Von Kaulia KN. et al. Homotransplantation 
of the liver in humans. Surg Gynecol Obstet 1963: 117:659-676. 
4. Starzl TE. Iwatsuki S. Van Thiel DH. et al. Evolution of liver trans-
plantation. Hepatology 1982: 2:614-636. 
5. Rolles K. Williams R. Neuberger J. Calne R. The Cambridge and 
King's College Hospital experience of liver transplantation. 1968-
1983. Hepatology 1984; 40suppl):50S-55S. 
6. Caine RY. Rolles K. White DJG. et a1. Cyclosporin A initially as the 
only immunosuppressant in 34 recipients of cadaveric organs: 32 
kidneys. 2 pancreases, and 2 livers. Lancet 1979; 2: 1033-1036. 
7. Starzl TE, Klintmalm GBG. Porter KA. et al. Liver transplantation 
with the use of cyclosporin A and prednisone. N Engl J Med 1981: 
305:266-269. 
8. Gordon RD. Todo S. Tzakis AG. et al. Liver transplantation under 
cyclosporine: a decade of experience. Transplant Proc 1991; 23: 1393-
1396. 
9. Abbasoglu O. Levy MF. Brkic BB, et aI. Ten years of liver 
transplantation: an evolving understanding of late graft loss. Trans-
plantation 1997; 64:1801-1807. 
10. Asfar S. Metrakos P. Fryer J, et al. An analysis of late deaths after liver 
transplantation. Transplantation 1996: 61: 1377-1388. 
I L Goss JA. Shackleton CR. McDiarmid SV. et aI. Long-term results of 
pediatric liver transplantation: an analysis of 569 transplants. Ann Surg 
1998; 228:411-420. 
12. Seaberg EC. Belle SH. Beringer KC. et al. Liver transplantation in the 
United States from 1987-1998: updated results from the Piu-UNOS 
Liver Transplant Registry. Clin Transplant 1998:17-37. 
13. Amersi F. Farmer DG. Busuttil RW. Fifteen-year experience with 
adult and pediatric liver transplantation at the University of California. 
Los Angeles. Clin Transplant 1998:255-261. 
14. Mirza DF. Gunson BK. McMaster P. Liver transplantation in 
Birmingham: indications. results. and changes. Clin Transplant 1996: 
217-221. 
15. Hemming AW. Cattral MS. Greig PD. et al. The University of Toronto 
liver transplant program. Clin Transplant 1996: 177-185. 
16. Zetterman RK. Belle SH. Hoofnagle JH. et al. Age and liver 
transplantation: a repon of the Liver Transplantation Database. Trans-
plantation 1998; 66:500-506. 
17. Jain AB. Vee LD. Nalesnik MA. et al. Comparative incidence uf de 
novo nonlymphoid malignancies after liver transplantation under ta-
crolimus using surveillance epidemiologic end result data. Transplan-
tation 1998; 66:1193-1200. 
18. Jain A. Reyes J. Kashyap R. et al. What have we learned about primary 
liver transplantation under tacrolimus immunosuppression? Long-term 
follow-up of the first 1000 patients. Ann Surg 1999; 230:441-448. 
19. Detre KM. Lombardero M. Belle S. et al. Influence of donor age on 
graft survival after liver transplantation-United Network for Organ 
Sharing Registry. Liver Transplant Surg 1995: 1:311-319. 
20, Marino IR. Doyle HR. Erighetti L. et al. Effect of donor age and sex 
on the outcome of liver transplantauon. Hepatology 1995: 22(6): 
1754-1762. 
21. Doyle HR. Manno IR. Jabbour N. et al. Early death or retransplanta-
tion in adults after onhot0plc liver transplantauon. Can out<:ume be 
predicted? Transplantation 1994: 57(7): 1028-1036. 
22. Facciu(o M. Heidt D. Guarerra J. et al. Retransplantauon for late liver 
graft failure: predictors of monaJity. Liver Transplant 2000: 6: 174-
179. 
7 
Ann. Surg •• October 2000 
23. Todo S. Fung JJ. Starzl TE. et at. Single-center experience with 
primary onhotopic liver transplantation with FK506 immunosuppres-
sion. Ann Surg 1994: 220:297-308. 
24. Fung JJ. Todo S. Jain A. et al. Conversion from cyclosporine to FK506 
in liver allograft recipients with cyclosporine-related complications. 
Transplant Proc 1990; 22:6-12. 
25. U.S. Multicenter FK506 Liver Study Group. A comparison of tacroli-
mus (FK 506) and cyclosporine for immunosuppression in liver trans-
plantation. N Engl J Med 1994: 331: 1110-1115. 
26. European FK506 Multicentre Liver Study Group. Randomised trial 
comparing tacrolimus (FK506) and cyclosporin in prevention of liver 
allograft rejection. Lancet 1994; 344:423-428. 
27. Fung 11. Eliasziw M. Todo S, et al. The Pittsburgh randomized trial of 
tacrolimus compared to cyclosporine for hepatic transplantation. 
J Amer Coli Surg 1996: 183(2):117-125. 
28. Ludwig J. Hashimoto E. Porayko MK. et al. Failed allografts and 
causes of death after orthotopic liver transplantation from 1985 to 
1995: decreasing prevalence of irreversible hepatic allograft rejection. 
Liver Transpl Surg 1996; 2:185-191. 
29. Jain AB. Fung 11. Todo S. et al. Incidence and treatment of rejection 
episodes in primary orthotopic liver transplantation under FK506. 
Transplant Proc 1991; 23:928-930. 
30. Davern TJ. Lake JR. Recurrent disease after liver transplantation. 
Semin Gastrointest Dis 1998; 9:86-109. 
31. Neuberger 1. Recurrence of primary biliary cirrhosis. primary scleros-
ing cholangitis. and autoimmune hepatitis. Liver Transpl Surg 1995; 
1(Suppl):I09-115. 
32. Samuel D. Feray C, Bismuth H. Hepatitis viruses and liver transplan-
tation. J Gastroenterol Hepatol 1997; 12:S335-S341. 
33. Hart J. Busuttil RW. Lewin KJ. Disease recurrence following liver 
transplantation. Am J Surg Pathol 1990; 14(Suppl): 79 -91. 
34. Laine J. Jalanko H. Saarinen-Pihkala UM. et al. Successful liver 
transplantation after induction chemotherapy in children with inoper-
able. multi focal primary hepatic malignancy. Transplantation 1999; 
67: 1369 -1372. 
35. Gerber DA. Arcement C. Carr B. et al. Use of intrahepatic chemo-
therapy to treat advanced pediatric hepatic malignancies. J Pediatr 
Gastroenterol Nutr 2000: 30:137-144. 
36. Jain A. DiMartini A. Kashyap R. et al. Long-term follow-up after liver 
transplantation for alcoholic liver disease under tacrolimus. Transplan-
tation (in press). 
37. Mateo R. Demetris AJ. Sico E. et al. Early detection of de novo 
hepatitis C infection in patients after liver transplantation by reverse 
transcriptase polymerase chain reaction. Surgery 1993; 114:442-448. 
38. Boker KH. Dalley G. Bahr MJ. et a!. Long-term outcome of hepatitis 
C virus infection after liver transplantation. Hepatology 1997; 25:203-
210. 
39. Gane EJ. Portmann BC. Naoumov NV. et al. Long-term outcome of 
hepatitis C infection after liver transplantation. N Engl J Med 1996; 
334:815-820. 
40. Marsh JW. Dvurchik I. Bonham CA. et a!. Is the pathologic TNM 
staging system for patients with hepatoma predictive of outcome'? 
Cancer 2000; 88:538-543. 
41. Markmann JF. Markowitz JS. Yersiz H. et a!. Long-term survival after 
retransplantation of the liver. Ann Surg 1997; 226:408-418. 
Discussion 
DR. WILLIAM C. MEYERS (Worcester. Massachusetts): This will 
likely become one of the most quoted papers in transplantation 
over the next years. The authors have provided us with simple. 
accurate answers to questions that patients. referring physicians. 
and others often ask us-the real results of Ii ver transplantation. 
The authors' stratifications with respect to survival are straightfor-
ward. understandable. and beautifully presented. 
r 
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The global nature of these statistics is what is important. They 
take into account all variables, be they the aggressive nature of a 
donor policy, severity of disease. or types of immunosuppression. 
It is also particularly appropriate for these numbers to come from 
our leading liver transplant center for the past two-plus decades. 
I have two questions. One is sort of a test of selectivity: Are 
living-related or other split livers included in these data? Second, 
how do the authors suggest that we use these data? As gold 
standards? As middle-of-the-road data? Do they have appropriate-
ness with respect to something like Medicare approval guideline 
numbers? In other words, what do you see as the limitations of 
your own data? 
PREsENTER DR. JOHN J. FUNG (Pittsburgh, Pennsylvania): This 
series does not include our living donor experience. These are 
cadaveric primary transplants. We have not performed many living 
donor transplants at Pittsburgh. 
I suspect that. like many other series on analysis of long-term 
outcome, if living donors are to be included. they will need to be 
stratified in some way due to the differences in severity of patients, 
of recipient characteristics, as well as differences in preservation 
and donor qUality. 
What do I consider as being the principal limitation of the data? 
As you can imagine, the amount of data that can be presented in 
such a setting is limited. We have done subset analysis in more 
detail. For instance, our analysis of patients with malignancy has 
shown that there are characteristics that are quite favorable. and we 
have developed models to predict such outcomes. 
What can this data be used for? They can be used to influence 
policies regarding coverage. For example, Medicare continues to 
deny coverage for patients with hepatocellular carcinoma, even if 
they have favorable characteristics. Such policymakers need to be 
educated regarding these advances. 
I think the principal limitation of this study is basically that it 
doesn't go into details regarding specifics. But I do believe that it 
does give one an opportunity to look at the evolution of liver 
transplantation through its entire history. 
DR. STUART J. KNECH11..E (Madison. Wisconsin): John, I would 
like to congratulate you and your colleagues at the University of 
Pittsburgh for a truly remarkable series of 4,000 liver transplants 
performed at your center. Since Dr. Starzl and his team, now led 
by Dr. Fung, established liver transplantation as definitive therapy 
for end-stage liver disease, your group has pioneered the develop-
ment of technical aspects of liver transplantation. introduced 
FK506 as an immunosuppressant. trained many of the liver trans-
plant surgeons in America. and compiled by far the largest series 
of liver transplants. You are therefore in a unique position to 
evaluate the long-term outcome of liver transplantation. I have four 
questions. 
First. in view of your observation that infection and cancer 
account for 40% of deaths long-term. would it not be reasonable to 
conclude that immunosuppression has been too heavy-handed for 
optimal long-term management? You and your group have re-
ported a gradual withdrawal of all immunosuppression in a se-
lected series of liver transplant patients with stable graft function. 
Based on the data you have just shown us. what is your recom-
mendation with regard to long-tenn management of immunosup-
pression in liver transplant recipients'! How much is just right 
based on the data you showed? 
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Secondly. it is clear from your results that compared to the 
transplanted heart. lung, and kidney, the liver is far less susceptible 
to chronic rejection, hence the slow rate of graft loss that you 
showed. Why do you think the liver is relatively less susceptible to 
chronic rejection? 
Thirdly, you identified several recipient groups who have poor 
long-tenn outcomes, including patients greater than 60 years of 
age, patients with alcoholic liver disease. patients with hepatitis B 
and C, and retransplants. How should these facts influence selec-
tion of these particular patient groups for transplantation? 
Fourthly, no one knows exactly how long a transplanted donor 
liver can function. Did you find any adverse effect of transplanting 
an older donor liver into a very young recipient in terms of 
long-term function or outcome? 
DR. FUNG: Dr. Knechtle. it is an honor for me to have you review 
the paper also, because the University of Wisconsin has been such 
a tremendous contributor to the field of liver transplantation and I 
think has made seminal contributions, one of which has been the 
use of the UW solution for our preservation. To address your 
questions: 
First issue, reduction of long-term immunosuppression as a way 
to control the incidence of infection and cancer. As you alluded to, 
we have been involved in prospective weaning trials. Thus far, we 
have only prospectively weaned about 100 patients, of which there 
are now 40 patients who are off immunosuppression. This contin-
ues to be a slow process because of the strict requirements to enter 
that weaning protocol; however. this a trial-and-error study. We 
need to try to understand what factors are associated with toler-
ance. The NIH is sponsoring the Immune Tolerance Network, 
which will focus on assays to predict who will be tolerant I think 
larger weaning trials should await this type of effort, either as a 
way to better predict who can be weaned off immunosuppression 
or to serve as an adjunct study for scientific purposes. But our 
policy has been to try to lower the immunosuppression in these 
patients as quickly as possible. I do believe that the liver has 
tolerogenic qualities and they do have a lot to do with the chimer-
ism concept that Dr. Stanl has proposed. particularly given the 
hematopoietic nature of the liver. 
Regarding the utility of culling patients at high risk of dying 
from transplantation. it depends on what society considers as an 
appropriate threshold. If, as Dr. lack Lake has proposed. a 50% 
5-year survival is the minimum, then patients over the age of 60 
can still be transplanted. I think what we need to do as a group of 
transplant surgeons and physicians is to understand that within 
"high-risk" groups, such as hepatomas and retransplantation. there 
are patients who can be transplanted with good outcomes. It is up 
to us to identify further by these types of analyses what kinds of 
patients in the high-risk category are going to do well. 
Lastly, we have looked at older donor (>50 years) into younger 
recipients. There is an overall negative impact. but the risk appears 
to be frontloaded. 
DR. GORAN B. KLtNTMALM (Dallas. Texas): Pittsburgh has not 
only blazed the path for us technically but also immunologically 
and not the least in transplant policy. And Dr. Fung, you yourself 
have taken a tremendous load in this latter feat. 
Two of the previous discussants have touched on the question of 
the groups with poor survivals. the retransplantations. What is now 
ten Odi t ,,' rc. 
500 Jain and Others 
your policy in Pittsburgh? You have never been afraid to take the 
lead in the past. and I am sure you do that now as well. 
DR. FUNG: Thank you for your question about risk factors in 
retransplants and transplants in elderly patients. We evaluate our 
elderly physiologically. I think that is probably the only way to do 
justice to patients in that category. If they are physiologically 
younger than they appear, then we will transplant them. 
From a retransplant standpoint. patients who have reached crit-
ical status 2A with renal failure. advanced malnutrition, and other 
risk factors for which we would not consider primary transplants, 
would not be retransplanted in the current era. 
DR. NANCY L. ASCHER (San Francisco, California): To me the 
most important information that came out of this analysis was the 
issue of recurrent disease, in particular those patients with hepatitis 
B, hepatitis C, and alcoholic liver disease. There have been tre-
mendous strides in treatments that prevent recurrent disease. 
Can you give the audience some idea of your approach to these 
patients? 
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DR. FUNG: Being from San Francisco, you appreciate the impact 
of viral hepatitis even more than we do with the patients we see in 
Pittsburgh. Hepatitis C is the fastest-growing indication for liver 
transplantation in the United States, and we all know that close to 
100% of them will become reinfected. With international contri-
butions to understanding how to prevent them, pharmaceutical 
agents to treat recurrent hepatitis C or prophylaxis hepatitis C, 
we hope that there will be a way to decrease the long-term graft 
losses. Having said that. however, we do not see a statistically 
significant decrease at this point. I still think it is quite a 
satisfactory survival without worrying too much about recurrent 
disease. 
But alcoholic liver disease was quite surprising in the long-term 
decrease in survival. It was clear that these patients died primarily 
of cardiovascular and de novo cancers. When we analyzed the risk 
factors for them, alcohol and smoking tend to go hand in hand in 
these patients. I think a more careful follow-up in terms of ear, 
nose, and throat and digestive follow-up for malignancy is prob-
ably one way to either prevent them or catch them at a stage where 
we can treat them. 
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